The cost of the new trials will be minimal compared to the phase 3 trial.
The additional burden on capital will be minor.
It will also be cheaper than the current P2 trial
A lot of benefit in economies of scale, as the manufacturing platform, partnerships and infrastructure have already set up.
We're using the same process, just targeting different indications.
Business as usual for the Prima team.
Funding will most likely occur before commercialisation, but I would suspect any such raising or deal will be post P2 results. If it happens prior to this, there will be issues.
The cost of the new trials will be minimal compared to the phase...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.005(1.25%) |
Mkt cap ! $588.3M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.5¢ | 39.8¢ | $2.431M | 6.045M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6880 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 85353 | 3 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |